Accelerated approval: unfulfilled promises for FDA’s expedited review program

27 May 2022 - As practicing physicians, approval by the U.S. FDA reassures us that the treatments we prescribe our patients ...

Read more →

Where is the PHARMAC review?

28 May 2022 - “It has been three months to the day since the Minister received the PHARMAC review, why ...

Read more →

Review of discount rate in the PBAC Guidelines

25 May 2022 - The Commonwealth has entered into a new Strategic Agreement in relation to reimbursement, health technology assessment ...

Read more →

Medicines Australia puts spotlight on reform priority for the next Government

20 May 2022 - Medicines Australia has set the scene for major health reform by the next Government by alerting ...

Read more →

TLV reconsiders subsidy of CGRP inhibitors

18 May 2022 - TLV has started a review of the CGRP inhibitors. ...

Read more →

Discount rate adjustment for the health of future generations

17 May 2022 - Medicines Australia has released a video detailing the need for Australia to adjust its discount rate ...

Read more →

Calls for Health Minister to release final report from PHARMAC review

11 May 2022 - Health Minister Andrew Little is facing calls to release the final report from a review of ...

Read more →

Next Health Minister must restart the National Medicines Policy Review

10 May 2022 - Medicines Australia has released a video outlining the importance of restarting the National Medicines Policy Review ...

Read more →

Congress moves toward reforming FDA accelerated approvals, but with pharma friendly concessions

4 May 2022 - House lawmakers are moving a little closer toward cracking down on drugmakers that game the FDA’s ...

Read more →

What is the HTA review and why is it important for Australia’s health system?

3 May 2022 - Medicines Australia has released its fourth video in its Federal Election series, explaining the upcoming independent ...

Read more →

It’s time to fix the FDA by breaking it up

11 April 2022 - A new investigation about the agency’s failures underscores the need for a separate agency to keep our ...

Read more →

Health Technology Assessment Review Reference Committee will drive reform to support Australian patients

10 April 2022 - The Health Technology Assessment Review Reference Committee announced (via the Department of Health website) is tasked ...

Read more →

Life Saving Drugs Program – medicines reviews recommendations

7 April 2022 - This document outlines 51 recommendations from the Life Saving Drugs Expert Panel review. ...

Read more →

ICER publishes white paper evaluating reforms to orphan drug development, pricing and coverage

7 April 2022 - The white paper presents an analysis of the potential risks and benefits of reforms seeking to ...

Read more →

Consultation now open - review of base case discount rate at 3A.1 of the PBAC Guidelines

5 April 2022 - The Commonwealth has entered into a new Strategic Agreement in relation to reimbursement, health technology assessment ...

Read more →